NCT03452150 - D-0316 First Time in Patients Ascending Dose Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

August 28, 2020

Study Completion Date

December 31, 2020

Conditions

Advanced Non Small Cell Lung Cancer

Interventions

DRUG

D-0316

If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined

Trial Locations (3)

130012

Research Site, Changchun

200030

Research Site, Shanghai

310052

Research Site, Hangzhou